Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.80 |
| ▸ | EGFR | P00533 | 6/20 | 0.62 |
| ▸ | JAK3 | P52333 | 4/20 | 0.60 |
| ▸ | JAK2 | O60674 | 3/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | BLK | P51451 | 1/20 | 0.59 |
| ▸ | ITK | Q08881 | 1/20 | 0.59 |
| ▸ | JAK1 | P23458 | 2/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | CDK7 | P50613 | 1/20 | 0.57 |
| ▸ | CCNH | P51946 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449887 | 0.93 | BTK (0.70) | BTKEGFRJAK3JAK2LRRK2 | |
| SCHEMBL12813134 | 0.89 | BTK (1.00) | BTKEGFRJAK3JAK2BLK | |
| SCHEMBL19961250 | 0.88 | BTK (0.62) | BTKEGFRJAK3JAK2LRRK2 | |
| SCHEMBL21648593 | 0.87 | BTK (0.62) | BTKEGFRJAK3JAK2LRRK2 | |
| SCHEMBL17071433 | 0.85 | BTK (0.85) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL15640174 | 0.85 | BTK (0.89) | BTKEGFRJAK3JAK2BLK | |
| SCHEMBL17071407 | 0.84 | BTK (0.88) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL15638700 | 0.84 | BTK (1.00) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL16144740 | 0.83 | BTK (0.81) | BTKEGFRJAK3JAK2LRRK2 | |
| SCHEMBL15637442 | 0.83 | BTK (0.79) | BTKEGFRJAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4115886-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | Pharmacyclics LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CORNELL UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210145835-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210121463-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200368235-A1 | IBRUTINIB COMBINATION THERAPY | PHARMACYCLICS LLC (US) | 2020-11-26 | — | — | US | disclosed |
| US-10695350-B2 | Methods of treating and preventing graft versus host disease | PHARMACYCLICS LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200061066-A1 | METHODS FOR TREATING B CELL PROLIFERATIVE DISORDERS | CORNELL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| US-10314842-B2 | Methods for treating B cell proliferative disorders | CORNELL UNIVERSITY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20150157634-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| WO-2015061751-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061752-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015023703-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
| WO-2015017812-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
| WO-2015002894-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014168975-A1 | IBRUTINIB COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014159745-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121463-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | BTK 8/4885EGFR 2307/4885JAK3 329/4885 |
| US-20150157634-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | BTK 2/4885EGFR 1605/4885JAK3 202/4885 |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | HDAC1, HDAC4, HDAC2 | BTK 1268/4885EGFR 1866/4885JAK3 1100/4885 |
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CDK4, BCL6, BCL6B | BTK 4/4885EGFR 1336/4885JAK3 87/4885 |
| US-10695350-B2 | Methods of treating and preventing graft versus host disease | BLK, DCK, CILK1 | BTK 8/4885EGFR 2307/4885JAK3 329/4885 |
| US-20210145835-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | ERBB2, EGFR, ERBB3 | BTK 10/4885EGFR 2/4885JAK3 205/4885 |
| US-10314842-B2 | Methods for treating B cell proliferative disorders | CDK4, BCL6, BCL6B | BTK 4/4885EGFR 1336/4885JAK3 87/4885 |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | BTK 2/4885EGFR 1605/4885JAK3 202/4885 |
| US-20200061066-A1 | METHODS FOR TREATING B CELL PROLIFERATIVE DISORDERS | CDK4, BCL6, BCL6B | BTK 4/4885EGFR 1336/4885JAK3 87/4885 |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | BTK, LCK, LYN | BTK 1/4885EGFR 544/4885JAK3 29/4885 |
| US-20200368235-A1 | IBRUTINIB COMBINATION THERAPY | BTK, SYK, LYN | BTK 1/4885EGFR 679/4885JAK3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.